Catalog No.: PC-49650Not For Human Use, Lab Use Only.
AM095 (AM-095) is a potent, selective and orally active lysophosphatidic acid type 1 receptor (LPA1) antagonist with IC50 of 0.98 and 0.73 uM for hLPA1 and mLPA1 in GTP S binding assays, respectively, with no LPA1 agonism.
AM095 (AM-095) is a potent, selective and orally active lysophosphatidic acid type 1 receptor (LPA1) antagonist with IC50 of 0.98 and 0.73 uM for hLPA1 and mLPA1 in GTP S binding assays, respectively, with no LPA1 agonism.
AM095 inhibited LPA-driven chemotaxis of CHO cells overexpressing mouse LPA1 (IC50=778 nM) and human A2058 melanoma cells (IC50=233 nM) in function assays.
AM095 inhibited LPA1-driven chemotaxis of both human A2058 melanoma cells (IC50 =0.23 uM) and mouse LPA1/CHO cells (IC50=0.78 uM)。
AM095 dose-dependently reduced LPA-stimulated histamine release, attenuated bleomycin-induced increases in collagen, protein, and inflammatory cell infiltration in bronchalveolar lavage fluid in vivo.
AM095 decreased kidney fibrosis in a mouse unilateral ureteral obstruction model.
